HSiFox-T7

HSiFox-T7 is an experimental, triple-action therapeutic designed to treat HER3-positive solid tumors. It consists of a 5′-triphosphate-modified siRNA targeting the FOXC1 transcription factor, encapsulated within a HER3-targeted HPK nanocapsid. The HPK nanocapsid, engineered from adenovirus penton base protein and neuregulin, facilitates membrane penetration and specific binding to HER3-overexpressing cells. Once delivered, the siRNA silences FOXC1, a master regulator of tumor aggressiveness and metastasis, while the 5′-triphosphate moiety (incorporated via T7 polymerase transcription) activates the RIG-I pathway to induce a tumor-intrinsic type I interferon response. This dual mechanism of gene silencing and immune activation has demonstrated efficacy in suppressing tumor growth and metastasis in preclinical models of melanoma and triple-negative breast cancer.

Other names

5′-triphosphate-modified FOXC1 siRNAT7-transcribed FOXC1 siRNAT-7-transcribed FOXC1 siRNAT 7-transcribed FOXC1 siRNA